Brexit: Pharmacovigilance Requirements for UK MAHs
Following the Brexit, the MHRA posted an updated guidance to become familiar with the pharmacovigilance requirements for UK marketing authorization holders (MAHs).
MHRA´s guidance on UK pharmacovigilance requirements
In the blog post, the agency provides sources of guidance and further information, including the following:
- In general, the EU Good Pharmacovigilance Practices (GVP, EudraLex Volume 9) continues to apply in the UK.
- There are some exceptions and modifications to the EU GVP that apply to UK MAHs and the MHRA.
- Guidance on the submission of the summary of pharmacovigilance system details and on the UK QPPV and the pharmacovigilance system master file (PSMF).
- Guidance on Pharmacovigilance procedures (e.g. submission of adverse drug reactions reports and PSURs).
- Frequently asked questions (available by contacting the respective pharmaceutical trade association via Email).
For more information please read the post Guidance on pharmacovigilance requirements for UK authorized products from 1 January 2021 on the MHRA blog.
Related GMP News
17.09.2025When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
17.09.2025Dealing with Systems without Audit Trail Functionality
17.09.2025Why is RCA (Root Cause Analysis) so important?
10.09.2025The Use of Hoses in Pharmaceutical Production
10.09.2025Revision of EU-GMP Chapter 1 planned with Consultation Phase
10.09.2025Audit Trail Review by the QP / Dealing with a Lack of Justification